In conclusion, CB ameliorates ICV-STZ-induced cognitive dysfunction in AD mice not only by modulating TLR4/MYD88/NF-κB signaling on the gut-brain axis, but also by regulating intestinal microbiota (Fig 7). This evidence concerns the gene NFKB1 and Alzheimer disease.